Rotasiil vs placebo
All serious adverse events · children
Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).
1 finding from 1 review
- RR 0.98 [0.92, 1.04]3 studies · 11646 participantsHigh
Findings
What do systematic reviews say?
4,918 questions · 5,537 findings · 1,803 reviews
No studies found 1,309 · 23.6%GRADE not reported 440 · 7.9%Very low 1,560 · 28.2%Low 1,292 · 23.3%Moderate 751 · 13.6%High 185 · 3.3%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Rotavac vs placebo
All serious adverse events · children
Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.93 [0.85, 1.02]3 studies · 8210 participantsModerate
Clotrimazole (partially absorbed from GI tract) vs another azole
Significant adverse events · patients with otomycosis
1 finding from 1 review
- no estimate extracted1 study · 174 participantsVery low
Gemcitabine vs BCG
Adverse events grade 3 to 5 Range of · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes grade III–V adverse events compared with BCG (very low certainty).
1 finding from 1 review
- Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes onlyRR 1 [0.21, 4.66]1 study · 80 participantsVery low
Gemcitabine vs Normal saline
Adverse events grade 3 to 5 Range of · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in grade III–V adverse events compared with saline (low certainty).
1 finding from 1 review
- Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes onlyRR 1.26 [0.58, 2.75]2 studies · 668 participantsLow
Vitamin D vs placebo or no intervention
Non‐serious adverse events · people with chronic liver diseases
1 finding from 1 review
- Vitamin D supplementation for chronic liver diseases in adults 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Carisbamate vs placebo
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · people with drug‐resistant focal epilepsy
Carisbamate may leads to higher adverse events: somnolence compared with placebo (low certainty).
1 finding from 1 review
- RR 1.82 [1.28, 2.58]4 studies · 2211 participantsLow
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
- RR 0.82 [0.52, 1.27]7 studies · 859 participantsModerate
Sclerotherapy (STS) vs sclerotherapy (any sclerosant)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (STS) probably leads to higher adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
- RR 2.1 [1.14, 3.85]2 studies · 323 participantsModerate
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic saline) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
- RR 0.89 [0.58, 1.36]2 studies · 288 participantsModerate
Sclerotherapy vs placebo
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy probably leads to higher adverse events ‐ matting ( compared with placebo (moderate certainty).
1 finding from 1 review
- RR 4.06 [1.28, 12.84]3 studies · 528 participantsModerate
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (low certainty).
1 finding from 1 review
- RR 0.31 [0.01, 7.53]1 study · 99 participantsLow
Foam vs sclerotherapy (any sclerosant)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Foam may leads to higher adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (low certainty).
1 finding from 1 review
- RR 6.12 [1.04, 35.98]2 studies · 187 participantsLow
Laser therapy vs sclerotherapy (any sclerosant)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Laser showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (moderate certainty).
1 finding from 1 review
- RR 1 [0.46, 2.19]2 studies · 162 participantsModerate
Laser plus sclerotherapy vs sclerotherapy (any sclerosant)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Laser plus sclerotherapy showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (low certainty).
1 finding from 1 review
- RR 0.83 [0.21, 3.28]2 studies · 656 participantsLow
Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).
1 finding from 1 review
- RR 0.78 [0.51, 1.2]2 studies · 191 participantsModerate
Sclerotherapy plus compression vs sclerotherapy (any sclerosant)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy plus compression showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy alone (low certainty).
1 finding from 1 review
- RR 1.84 [0.17, 19.62]1 study · 96 participantsLow
Adjuvant chemotherapy vs no chemotherapy
Non‐serious adverse events · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
- Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Idebenone vs placebo
Non‐serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline
Idebenone showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory… 2021 · Cochrane Headline outcomes onlyRR 1 [0.88, 1.13]1 study · 66 participantsLow
Bamlanivimab/etesevimab vs placebo
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 1.15 [0.83, 1.59]1 study · 1035 participantsLow